Today, the medical sector of Hong Kong stocks suffered a setback. By 10:54, Alibaba Health Information Technology was down 6.46%, Shisiyao Group was down 5.04%, Ping An Healthcare And Technology was down 4.63%, and Keji Pharmaceutical-B was down 3.99%. Hang Seng Medical ETF (513060) fell 0.13% in intraday trading. The share of the fund has grown by 122% in the past three months, and by 682% in the past six months, breaking through the 500 million yuan mark in one fell swoop, reaching the threshold for inclusion in the two financing targets.

On the news side, the relevant departments issued the "Clinical value-oriented Clinical Research and Development guidance Center for antineoplastic drugs", emphasizing the establishment of research and development topics based on the needs of patients and the design of clinical trials that reflect the needs of patients. Guojin Securities said that the guiding principles will further promote the healthy and sustainable development of domestic innovative drugs and promote local innovation differentiation. The leading local clinical CRO companies, which are optimistic about local drug discovery and the boost of preclinical CRO market demand, and provide scientific, standardized, high-quality and efficient clinical trial services, will gain more market share.

Hang Seng Medical ETF (513060) closely tracks the Hang Seng Healthcare Index, covering a number of sub-areas, including pharmaceuticals, biotechnology, health care technology, health care equipment and supplies, to fully meet the configuration needs of investors for the health care industry.